VivoSeq
Other

Peri-Implantitis

13

Pipeline Programs↗

8

Active Trials↗

7

Companies Involved↗

Peri-Implantitis is an emerging landscape with 13 programs across 7 companies. The most active players are Dexcel Pharma Technologies Ltd., OraPharma, AstraZeneca. 6 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

25/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

D

Dexcel Pharma Technologies Ltd.

1 program

Phase 2O

OraPharma

1 program

Phase 3AstraZeneca logo

AstraZeneca

1 program

Phase 3T

Triax

1 program

ApprovedW

WestVac Biopharma Co., Ltd.

1 program

PreclinicalSanofi logo

Sanofi

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

28

clinical trials

Completed19 · 68%
Not yet recruiting4 · 14%
Recruiting2 · 7%
Enrolling by invitation2 · 7%
Unknown status1 · 4%

Clinical Trials

Trial Activity

28 trials

Efficacy of a Natural Bioactive Gel as an Adjunct to Standard Therapy in the Treatment of Peri-Implantitis: A Randomized Controlled Split-Mouth Clinical Trial
Recruiting·UUniversity of Pavia·Preclinical·NCT07088679·20 enrolled
Non-surgical Treatment of Peri-implant Pockets With H42
Recruiting·BBioteck S.p.A.·N/A·NCT07680491·56 enrolled
Non-Surgical Treatment of Peri-implantitis with Systemic Azithromycin or Placebo
Not yet recruiting·UUniversity of Santiago de Compostela·Phase 4·NCT06715150·52 enrolled
Association of Metrnl Expression With IL-1β and TNF-α in Patients With Peri-Implantitis: Potential as a Novel Biomarker
Not yet recruiting·AAtaturk University·N/A·NCT07697729·60 enrolled
Regenerative Outcomes for Peri-implant Bony Defects Using Amnion-chorion Barrier vs. Collagen Membrane: a Randomized Controlled Clinical Trial
Not yet recruiting·LLoma Linda University·Preclinical·NCT07032259·56 enrolled
Patient-Centered Outcomes Throughout Peri-Implantitis Therapy: A Multicenter Prospective Observational Study
Not yet recruiting·UUniversity of Barcelona·N/A·NCT07694323·45 enrolled
Regenerative Treatment of Peri-implantitis: A Comparison of the Reinforced PTFE Mesh (RPM) and the Collagen Membrane in the Submerged Approach: a Randomized Controlled Clinical Trial
Enrolling by invitation·UUniversity of Michigan·Preclinical·NCT06153212·32 enrolled
20-25 Year Follow-Up After Surgical Treatment of Peri-Implantitis Using a Bone Substitute With or Without a Resorbable Membrane: A Longitudinal Study
Enrolling by invitation·Kristianstad University·N/A·NCT06648564·20 enrolled
Arestin - Use in Subjects With Peri-Implantitis
Completed·OOraPharma·Phase 3·NCT01539564·215 enrolled
Surgical Treatment of Peri-implantitis With and Without Systemically Adjunctive Antibiotics
Completed·—·Phase 4·NCT02185209·77 enrolled
Surgical Treatment of Peri-implantitis
Completed·GGöteborg University·Phase 4·NCT01857804·100 enrolled
Arestin - Use in Subjects With Peri-Implantitis (With Subgingival Microbiological Evaluation)
Completed·OOraPharma·Phase 3·NCT01517334·208 enrolled
Systemic Amoxicillin Plus Metronidazole in Peri-implantitis Treatment
Completed·UUniversity Medical Center Groningen·Phase 4·NCT04149327·62 enrolled
Triclosan Toothpaste in the Maintenance Phase of Peri-implantitis Treatment.
Completed·UUniversity of Guarulhos·Phase 3·NCT03191721·102 enrolled
The Efficacy and Safety of Chlorhexidine Gluconate Chip (Periochip®) in Therapy of Symptoms in Patients With Peri-implantitis
Completed·DDexcel Pharma Technologies Ltd.·Phase 2·NCT01079663·60 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)